Characterizing Pharmacogenetic Testing Among Children’s Hospitals

Abstract

Although pharmacogenetic testing is becoming increasingly common across medical subspecialties, a broad range of utilization and implementation exists across pediatric centers. Large pediatric institutions that routinely use pharmacogenetics in their patient care have published their practices and experiences; however, minimal data exist regarding the full spectrum of pharmacogenetic implementation among children's hospitals. The primary objective of this nationwide survey was to characterize the availability, concerns, and barriers to pharmacogenetic testing in children's hospitals in the Children's Hospital Association. Initial responses identifying a contact person were received from 18 institutions. Of those 18 institutions, 14 responses (11 complete and 3 partial) to a more detailed survey regarding pharmacogenetic practices were received. The majority of respondents were from urban institutions (72%) and held a Doctor of Pharmacy degree (67%). Among all respondents, the three primary barriers to implementing pharmacogenetic testing identified were test reimbursement, test cost, and money. Conversely, the three least concerning barriers were potential for genetic discrimination, sharing results with family members, and availability of tests in certified laboratories. Low-use sites rated several barriers significantly higher than the high-use sites, including knowledge of pharmacogenetics (P = 0.03), pharmacogenetic interpretations (P = 0.04), and pharmacogenetic-based changes to therapy (P = 0.03). In spite of decreasing costs of pharmacogenetic testing, financial barriers are one of the main barriers perceived by pediatric institutions attempting clinical implementation. Low-use sites may also benefit from education/outreach in order to reduce perceived barriers to implementation.

Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions

“…Although pediatric PGx needs extensive studies with most drugs, PGx screening may help pediatricians to adjust drug dose in order to reduce ADRs in children at risk [39]. Financial barriers (test reimbursement, test cost, and money) are the main obstacles perceived by pediatric institutions attempting clinical implementation [40]. Some countries have created Pharmacogenomics Networks for Drug Safety to develop personalized and genetic-based predictions of pediatric drug response and likelihood of experiencing ADRs [41].…”

The Utility of Pharmacogenetic-Guided Psychotropic Medication Selection for Pediatric Patients: A Retrospective Study

“…A recent survey of clinicians also indicated that 85% of respondents were concerned about the lack of clear guidance for clinical application [54]. This trend is troubling considering that many clinicians who use this type of test to guide clinical decision-making may not have an extensive pharmacogenetic knowledge to be sufficiently proficient in interpreting the test reports, among other perceived barriers [20,49,55]. Considering these factors, a multidisciplinary approach should be considered when interpreting pharmacogenetic test results.…”

Pharmacogenomics for Drug Dosing in Children: Current Use, Knowledge, and Gaps

“…CYP2D6 genotyping can be used to ensure safe prescription of codeine for children 9 . Pharmacogenomic studies have continued to discover gene‐drug associations that are applicable to children, and more of this pharmacogenomic information continues to be used to improve pediatric pharmacotherapy 10–12 …”